Highest-Cost Drugs Could Feel Biggest Pinch From Part B Step Therapy Policy
Executive Summary
Biosimilars for Remicade and Neulasta could get boost, and off-label Avastin use for age-related macular degeneration could increase, challenging Eylea and Lucentis.
You may also be interested in...
Step Therapy For Medicare Part B Drugs Will Lower Costs By 20%, HHS Projects
Beginning in 2019, Medicare Advantage plans may use step therapy in Part B, potentially including “cross management” with Part D drugs, under new guidance from the Centers for Medicare and Medicaid Services.
Step Therapy For Medicare Part B Drugs Will Lower Costs By 20%, HHS Projects
Beginning in 2019, Medicare Advantage plans may use step therapy in Part B, potentially including “cross management” with Part D drugs, under new guidance from the Centers for Medicare and Medicaid Services.
Mylan's Fulphila Sets Up The US Market For The Next Biosimilar Showdown
Mylan has priced its biosimilar version of pegfilgrastim at a 33% discount to Amgen's WAC for Neulasta, steeper than the 15% discount Pfizer initially offered for Inflectra. The commercial outcome for Fulphila could set the tone for future US biosimilars, which have yet to take off.